|
NR 3/2004
SUPLEMENT
|
|
|
|
|
|
|
|
|
Witrektomia z
daunorubicyną
Vitrectomy with daunorubicin
Krystyna Raczyńska, Andrzej Gębka,
Barbara Iwaszkiewicz-Bilikiewicz, Cezary Ciechanowski
Z Katedry i Kliniki Chorób Oczu Akademii Medycznej w Gdańsku
Kierownik: prof. dr hab. n. med. Barbara
Iwaszkiewicz-Bilikiewicz |
|
|
| Summary: |
Purpose: The
vitreoretinal re-proliferations (PVR) are the most
eminent cause of retinal surgery misfortunes.
Daunorubicin has been widely discussed as the
antimetabolic drug for PVR treatment for recent 20 years.
The aim of the study was to evaluate the usefulness of
daunorubicin, applied intravitreally during vitrectomy,
as an antiproliferative factor stopping the
vitreoretinal re-proliferations in eyes with
rhegamatogenous retinal detachment complicated with PVR.
Material and methods: Vitrectomy, with
daunorubicin infusion (1µg/ml), was performed in 6 eyes
with rhegamatogenous retinal detachment and PVR. In 6
other cases of retinal detachment, the gentamycine
(20mg/ml) solution was used as a vitrectomy infusion.
During the 12 months follow-up, the risk of PVR relapse
was evaluated.
Results: There was no signs of PVR relapse in the
eyes treated with daunorubicin during the 12 months
follow-up. As in the group of patients that had no
daunorubicin infusion the PVR re-proliferation occurred
in 2 of 6 operated eyes.
Conclusions: 12 months follow-up showed that
Daunorubicine could be a useful adjuvant drug reducing
the rate of re-proliferations in the patients with
rhegamatogenous retinal detachment. |
| Słowa kluczowe: |
odwarstwienie siatkówki,
PVR, witreoretinopatia proliferacyjna, witrektomia,
daunorubicyna, daunomycyna. |
| Key words: |
retinal detachment, PVR,
proliferative vitreoretinopathy, vitrectomy,
daunorubicin, daunomycin. |
|
|
|
|
|
|
